David Wang joins Response Biomedical's board of directors

Response Biomedical Corporation, a developer, manufacturer and marketer of rapid on-site diagnostic tests used for biodefense applications, announced this week that Dr. David Wang has been appointed to its board of directors as of October 11.
Wang is a senior managing director of Orbimed Asia and was most recently a managing director at WI Harper Group in a position responsible for healthcare investment in China. He earned his doctorate in developmental biology from the California Institute of Technology.
"Dr. David Wang brings a wealth of experience to our company and will undoubtedly make tremendous contributions to our success going forward", Dr. Peter Thompson, theexecutive chairman and interim CEO of Response Biomedical Corporation, said.
Wang previously served as head of business development at Siemens Medical Solutions, was the co-founder and executive vice president at First Genetic Trust and was the chairman of the SNP Consortium Management Committee during his tenure at Bristol-Myers Squibb. He received his M.D. from Peking University Medical School.
Response Biomedical has developed the RAMP platform for its on-site diagnostic tests, which provides high sensitivity and reliable information in minutes. In the non-clinical market, RAMP tests are provided for the environmental detection of West Nile Virus and biodefense applications, including the rapid on-site detection of anthrax, ricin, smallpox and botulinum toxin.